Navigation Links
Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
Date:5/14/2008

- Two 4-week cohorts will evaluate R7128 1000mg BID in HCV genotype 1 treatment-naive patients and R7128 1500mg BID in HCV genotypes 2 or 3

treatment-experienced patients -

PRINCETON, N.J., May 14 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) has commenced dosing two additional cohorts of a 4-week Phase 1 study of R7128 in combination with Pegasys(R) (peginterferon alfa-2a) plus Copegus(R) (ribavirin) in both treatment-naive and treatment-experienced patients chronically-infected with hepatitis C virus (HCV) genotypes 1, 2 and 3. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV that is being developed through Pharmasset's collaboration with Roche.

The purpose of this 4-week study is to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of R7128 in the clinically-relevant setting of combination therapy for chronic HCV infection. The previously planned Cohort 3 will continue dose-exploration with administration of R7128 1000mg twice-daily (BID) in treatment-naive patients with HCV genotype 1. Cohort 4 will evaluate R7128 1500mg BID administered in combination with Pegasys plus Copegus in treatment-experienced patients with genotypes 2 or 3 who did not achieve a sustained virologic response (SVR) with previous interferon-based therapy.

There will be 25 patients in each dose cohort with 20 patients randomized to receive R7128 and 5 patients randomized to receive placebo. After completing 4 weeks of the triple combination regimen and a follow-up period of 4 weeks of Pegasys plus Copegus, patients will receive an additional 16 to 40 weeks of open-label dosing of Pegasys plus Copegus under a separate protocol to complete the stand
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
10. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
11. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... , May 18, 2013 The ... , Occupy Psychiatry , and ... health care, announces a social media campaign showcasing ... traditional psychiatric model, which focuses on pathology and ... coincides with the American Psychiatric Association,s (APA) rollout ...
(Date:5/17/2013)...  Lakeland Industries, Inc. (NASDAQ: LAKE ), ... healthcare and to first responders on the federal, state ... the fiscal 2013 fourth quarter and year ended January ... market close and will conduct a conference call on ... (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ) The call ...
(Date:5/17/2013)... May 17, 2013   Shareholder rights attorneys  at ... Pharmaceutical, Inc. (NASDAQGS: AVEO) securities has filed a complaint ... Massachusetts .  The complaint alleges that ... Exchange Act of 1934 (the "Exchange Act") between January ... (Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO ) ...
Breaking Medicine Technology:New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3
(Date:5/20/2013)... Angeles, CA (PRWEB) May 20, 2013 Idol ... get bigger, thicker, darker and fuller eyelashes in a matter ... now available for online purchase with an extra pack offer ... Customers can easily access this offer on the Idol lash ... and showed to increase the eyelash density up to 82% ...
(Date:5/20/2013)... US Drug Watchdog says, "After talking with ... are now calling the transvaginal mesh failure issues the ... and the damages are literally beyond comprehension. We are ... women. According to the New York Times, in 2010, ... implanted vaginally to treat urinary incontinence. That was 2010 ...
(Date:5/20/2013)... 20, 2013 On May 14th, premiere ... testimonial about how one of its patients originally came ... after being diagnosed with giant papillary conjunctivitis. “Giant papillary ... the eye, and for one of our patients in ... allergy,” says the Medical Director of the Atlanta Vision ...
(Date:5/20/2013)... The Mesothelioma Victims Center says, "We are ... diagnosed with mesothelioma get shortchanged when it comes to ... members turned to a local personal injury law firm, ... and experienced mesothelioma lawyers in the nation. We also ... never even bother to explore their legal options, because ...
(Date:5/20/2013)... CA (PRWEB) May 20, 2013 ... MessageSolution, an industry leader in enterprise-class information archiving, ... Enterprise eDiscovery Platform 7.0, the latest release in ... all facets of the legal discovery lifecycle. MessageSolution ... in Los Angeles CA. , As the first ...
Breaking Medicine News(10 mins):Health News:Idol Lash Eyelash Growth Enhancer Now Offered Extra Pack for Limited Time Only at HealthCareSupplementz.com 2Health News:US Drug Watchdog Now Urges Transvaginal Mesh Failure Victims With Erosion To Call Them For The Names And Contacts Of The Best Women Attorneys 2Health News:Atlanta LASIK Practice Publishes a Patient’s Testimonial About Allergy to Contact Lenses 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For The Names Of The Nation's Best Mesothelioma Lawyers-Better Compensation 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For The Names Of The Nation's Best Mesothelioma Lawyers-Better Compensation 3Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 2Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 3Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 4
... Allscripts (Nasdaq: MDRX ),the leading provider ... use to improve healthcare, announced today that,it will ... months ended September,30, 2007 after the stock market ... Eastern Standard Time on the same day, Allscripts ...
... HILL, N.C., Oct. 23 As companies transform ... with the art of selling while maintaining a ... in facilitating the changeover,the manager/supervisor is one of ... In fact, call center leaders recommend reducing ...
... For Minimizing Commercial Exposure To Microbes, CHARLOTTE, ... provider of commercial hygiene products and services, today,announced ... at the ISSA/Interclean,trade show in Orlando from October ... number of germ reduction strategies that have been ...
... Answers.com(TM) (NASDAQ:,ANSW) today announced that it ... HealthiNation, a leading digital health media ... (See example at, http://www.answers.com/topic/cholesterol .) Answers.com ... such as business,health, travel, technology, science, ...
... LOUIS, Oct. 23 Cejka Search, a ... recently,announced that several of its leaders will ... conferences: The Medical Group,Management Association (MGMA) 2007 ... (ACPE) Fall Institute and the American College ...
... - TimeToTalk.org Provides Parents Timely Tips and Tools to Keep Youth ... ... have numerous methods,to trick their parents and keep their social behavior secret ... and social functions can help teens shield their drug or alcohol,use from ...
Cached Medicine News:Health News:Allscripts to Announce Third Quarter 2007 Results on November 8th 2Health News:Allscripts to Announce Third Quarter 2007 Results on November 8th 3Health News:Call Center Excellence: Managing Service-To-Sales Cultural Transformation 2Health News:Swisher Launches Germ-Free Zone at ISSA 2Health News:Answers.com Adds HealthiNation Video Content to Answer Engine(TM) 2Health News:Cejka Search Experts Present Latest Developments in Physician and Healthcare Employment at Leading Industry Conferences 2Health News:Cejka Search Experts Present Latest Developments in Physician and Healthcare Employment at Leading Industry Conferences 3Health News:Don't Be 'Tricked' By Your Teen This Month - It's Time To Talk With Teens About Drug and Alcohol Use 2Health News:Don't Be 'Tricked' By Your Teen This Month - It's Time To Talk With Teens About Drug and Alcohol Use 3Health News:Don't Be 'Tricked' By Your Teen This Month - It's Time To Talk With Teens About Drug and Alcohol Use 4
Duet Lumbar Allografts are comprised of a raised cancellous inner core providing biomechanical properties for rapid healing. Specially designed instruments facilitate the insertion of Duet Allografts...
Lumbar Allograft with Osteoactive advantage. Promotes bone formation and faster incorporation. Derived from the proven technology behind Grafton DBM. Maintains structural integrity and strength....
Seletz-Gelpi Laminectomy Retractor, self-retaining with arms bent at right angles....
Scoville-Haverfield Hemilaminectomy Retractor...
Medicine Products: